Article
Oncology
Christopher Nevala-Plagemann, Siddharth Iyengar, Andrew D. Trunk, Lisa Pappas, Benjamin Haaland, Ignacio Garrido-Laguna
Summary: In patients with left-sided RAS/RAF wild-type mCRC, anti-EGFR therapy may be superior to bevacizumab when added to first-line chemotherapy. Data shows that chemotherapy with bevacizumab remains the most widely used first-line treatment strategy for these patients in the United States, but treatment with an anti-EGFR agent is associated with improved overall survival.
JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK
(2022)
Article
Oncology
Marinde J. G. Bond, Karen Bolhuis, Olaf J. L. Loosveld, Jan Willem B. de Groot, Helga Droogendijk, Helgi H. Helgason, Mathijs P. Hendriks, Joost M. Klaase, Geert Kazemier, Mike S. L. Liem, Arjen M. Rijken, Cornelis Verhoef, Johannes H. W. de Wilt, Koert P. Jong, Michael F. Gerhards, Martinus J. van Amerongen, Marc R. W. Engelbrecht, Krijn P. van Lienden, I. Quintus Molenaar, Bart de Valk, Brigitte C. M. Haberkorn, Emile D. Kerver, Frans Erdkamp, Robbert J. van Alphen, Danielle Mathijssen-van Stein, Aysun Komurcu, Marta Lopez-Yurda, Rutger-Jan Swijnenburg, Cornelis J. A. Punt, Dutch Colorectal Canc Study Grp
Summary: This study compared the efficacy of different induction regimens in patients with initially unresectable colorectal cancer liver metastases. The results showed that FOLFOXIRI-bevacizumab was the preferred treatment for patients with right-sided primary tumor or RAS/BRAFV600E mutation, while the addition of panitumumab to FOLFOX or FOLFIRI in patients with left-sided and RAS/BRAFV600E wild-type tumor showed no clinical benefit but more toxicity.
Article
Medicine, General & Internal
Ozan Yazici, Gokhan Ucar, Osman Sutcuoglu, Nazim Serdar Turhal, Birol Yildiz, Michalis Karamouzis, Sinan Yavuz, Nuri Karadurmus, Nurullah Zengin, Ravit Geva, Huseyin Abali
Summary: This multinational registry study evaluated the real-life data on the survival of patients with metastatic colorectal cancer (mCRC). The study found that factors such as the patient's performance status, tumor location, and number of metastatic lesions at the time of diagnosis have an impact on the prognosis of mCRC.
CURRENT MEDICAL RESEARCH AND OPINION
(2022)
Review
Oncology
Udit Nindra, Adel Shahnam, Kate L. Mahon
Summary: Colorectal cancer is the third most common malignancy in Australia, with peritoneum being the second most common metastatic site. Treatment of colorectal peritoneal carcinomatosis (CPC) is limited to a small subset of patients, with 5-fluorouracil-based chemotherapy regimens showing benefits in overall and progression-free survival. The role of targeted agents like bevacizumab and cetuximab in CPC is still evolving, with promising results seen with bevacizumab but not with cetuximab in combination with systemic chemotherapy.
ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY
(2022)
Article
Oncology
Yi-Chia Su, Chih-Chien Wu, Chien-Chou Su, Meng-Che Hsieh, Ching-Lan Cheng, Yea-Huei Kao Yang
Summary: This study assessed the effectiveness of bevacizumab and cetuximab therapies in patients with metastatic colorectal cancer who did not undergo primary tumor resection. The results showed that cetuximab-based therapy had significantly better survival and conversion surgery rates compared to bevacizumab-based therapy in these patients.
Article
Oncology
Hans-Joachim Schmoll, Julia Mann, Fabian Meinert, Benjamin Garlipp, Kersten Borchert, Arndt Vogel, Eray Goekkurt, Ulrich Kaiser, Heinz-Gert Hoeffkes, Joern Ruessel, Stephan Kanzler, Thomas Edelmann, Helmut Forstbauer, Thomas Goehler, Carla Hannig, Bert Hildebrandt, Carsten Roll, Carsten Bokemeyer, Joerg Steighardt, Franziska Cygon, Stefan Ibach, Alexander Stein, Joseph Tintelnot
Summary: The study confirms the effectiveness and tolerability of FOLFOXIRI plus bevacizumab as a first-line treatment for mCRC, but challenges remain in its clinical implementation.
BRITISH JOURNAL OF CANCER
(2023)
Article
Cell Biology
Robin Beekhof, Andrea Bertotti, Franziska Boettger, Valentina Vurchio, Francesca Cottino, Eugenia R. Zanella, Giorgia Migliardi, Marco Viviani, Elena Grassi, Barbara Lupo, Alex A. Henneman, Jaco C. Knol, Thang V. Pham, Richard de Goeij-de Haas, Sander R. Piersma, Mariette Labots, Henk M. W. Verheul, Livio Trusolino, Connie R. Jimenez
Summary: This study used proteomics and phosphoproteomics to investigate the molecular basis of response to EGFR blockade in metastatic colorectal cancer (mCRC). The research found distinctive response signatures in the proteome and phosphoproteome, with sensitive tumors showing increased pathway activity related to MAPK inhibition and abundant tyrosine phosphorylation of cell junction proteins, while resistant tumors exhibited epithelial-mesenchymal transition and increased MAPK and AKT signaling. The analysis also revealed high kinase activity of ERBB2, EGFR, MET, Src, and ephrin kinase family members in cetuximab-resistant tumors. Inhibition of these hyperactive kinases resulted in growth inhibition of ex vivo and in vivo models. These findings highlight the potential value of phosphoproteomics in improving our understanding of anti-EGFR treatment and response prediction in mCRC, and identifying alternative drug targets in cetuximab-resistant tumors.
SCIENCE TRANSLATIONAL MEDICINE
(2023)
Article
Biochemistry & Molecular Biology
Andrea Sartore-Bianchi, Filippo Pietrantonio, Sara Lonardi, Benedetta Mussolin, Francesco Rua, Giovanni Crisafulli, Alice Bartolini, Elisabetta Fenocchio, Alessio Amatu, Paolo Manca, Francesca Bergamo, Federica Tosi, Gianluca Mauri, Margherita Ambrosini, Francesca Daniel, Valter Torri, Angelo Vanzulli, Daniele Regge, Giovanni Cappello, Caterina Marchio, Enrico Berrino, Anna Sapino, Silvia Marsoni, Salvatore Siena, Alberto Bardelli
Summary: This study aimed to use blood-based testing of RAS/BRAF/EGFR mutation levels to guide anti-EGFR therapy in patients with colorectal cancer. The results showed that rechallenge therapy with panitumumab, guided by liquid biopsies, had favorable outcomes compared to standard treatments. This suggests that liquid biopsies can effectively and safely guide treatment decisions in patients with mCRC.
Article
Medicine, General & Internal
Marwan G. Fakih, Lisa Salvatore, Taito Esaki, Dominik P. Modest, David P. Lopez-Bravo, Julien Taieb, Michalis V. Karamouzis, Erika Ruiz-Garcia, Tae-Won Kim, Yasutoshi Kuboki, Fausto Meriggi, David Cunningham, Kun-Huei Yeh, Emily Chan, Joseph Chao, Yaneth Saportas, Qui Tran, Chiara Cremolini, Filippo Pietrantonio
Summary: In this study, the combination of KRAS G12C inhibitor sotorasib and EGFR inhibitor panitumumab showed longer progression-free survival compared to standard treatment in patients with chemorefractory metastatic colorectal cancer.
NEW ENGLAND JOURNAL OF MEDICINE
(2023)
Review
Medicine, General & Internal
Gerardo Rosati, Michele Montrone, Carmen Pacilio, Alfredo Colombo, Giuseppe Cicero, Fernando Paragliola, Angelo Vaia, Luigi Annunziata, Domenico Bilancia
Summary: Although colorectal cancer is increasingly diagnosed in older patients, their representation in clinical trials is insufficient, leading to unclear treatment guidelines. Targeted therapy for elderly patients with wild-type RAS and BRAF is challenging due to potential toxicity. Comprehensive geriatric assessment and recent studies provide important data for differentiating treatment outcomes based on functional status.
JOURNAL OF CLINICAL MEDICINE
(2022)
Article
Medicine, General & Internal
Gerald W. Prager, Julien Taieb, Marwan Fakih, Fortunato Ciardiello, Eric Van Cutsem, Elena Elez, Felipe M. Cruz, Lucjan Wyrwicz, Daniil Stroyakovskiy, Zsuzsanna Papai, Pierre-Guillaume Poureau, Gabor Liposits, Chiara Cremolini, Igor Bondarenko, Dominik P. Modest, Karim A. Benhadji, Nadia Amellal, Catherine Leger, Loick Vidot, Josep Tabernero
Summary: In this study, researchers found that treatment with trifluridine-tipiracil plus bevacizumab could prolong overall survival in patients with metastatic colorectal cancer compared to trifluridine-tipiracil alone.
NEW ENGLAND JOURNAL OF MEDICINE
(2023)
Article
Oncology
Yoshitaka Saito, Kazuki Uchiyama, Yoh Takekuma, Yoshito Komatsu, Mitsuru Sugawara
Summary: A retrospective evaluation of mCRC patients receiving anti-EGFR monoclonal antibody treatment identified liver metastasis as an independent risk factor for skin toxicities and prophylactic administration of antibiotics as a preventive factor. The study suggests that preemptive antibiotic use can decrease the risk of skin toxicities during anti-EGFR treatment.
SUPPORTIVE CARE IN CANCER
(2023)
Article
Cell Biology
Yuanzhou Zhang, Shunshun Liang, Bowen Xiao, Jingying Hu, Yechun Pang, Yuling Liu, Juan Yang, Junpin Ao, Lin Wei, Xiaoying Luo
Summary: This study shows that ErbB3/EGFR receptor tyrosine kinase activity is increased in colorectal cancer cells, and miR-323a-3p can directly target both ErbB3 and EGFR, promoting apoptosis in CRC cells. Furthermore, miR-323a-3p acts as a multi-ErbBs inhibitor, enhancing sensitivity to gefitinib and preventing acquired resistance.
CELL DEATH & DISEASE
(2022)
Article
Oncology
Marla Lipsyc-Sharf, Fang-Shu Ou, Matthew B. Yurgelun, Douglas A. Rubinson, Deborah Schrag, Shaker R. Dakhil, Philip J. Stella, Douglas J. Weckstein, Donald B. Wender, Meredith Faggen, Tyler J. Zemla, Erica N. Heying, Samantha R. Schuetz, Stephanie Noble, Jeffrey A. Meyerhardt, Tanios Bekaii-Saab, Charles S. Fuchs, Kimmie Ng
Summary: The study investigated the efficacy of combining bevacizumab with irinotecan and cetuximab in patients with irinotecan-refractory metastatic colorectal cancer. Although there was no significant difference in progression-free survival between the two treatment groups, there was a statistically significant improvement in overall survival favoring the group that received bevacizumab in addition to irinotecan and cetuximab. Further investigation on this combination therapy is warranted.
Article
Multidisciplinary Sciences
Amna Mohamed Taha, Mohammad Mabrouk Aboulwafa, Hamdallah Zedan, Omneya Mohamed Helmy
Summary: Combining sorafenib with ramucirumab or panitumumab resulted in a significant decrease in sorafenib IC50, inhibited proliferation and angiogenesis, induced apoptosis, and altered the expression of various proteins related to cell cycle and apoptosis in HepG2 cancer cells. This suggests that ramucirumab may be a useful adjunct therapy to enhance sorafenib efficacy in HCC therapy.
SCIENTIFIC REPORTS
(2022)
Article
Integrative & Complementary Medicine
Oselys Rodriguez Justo, Patricia Ucelli Simioni, Dirce Lima Gabriel, Wirla Maria da Silva Cunha Tamashiro, Paulo de Tarso Vieira Rosa, Angela Maria Moraes
BMC COMPLEMENTARY AND ALTERNATIVE MEDICINE
(2015)
Review
Cell Biology
Bruno Rafael Ramos de Mattos, Maellin Pereira Gracindo Garcia, Julia Bier Nogueira, Lisiery Negrini Paiatto, Cassia Galdino Albuquerque, Caique Lopes Souza, Luis Gustavo Romani Fernandes, Wirla Maria da Silva Cunha Tamashiro, Patricia Ucelli Simioni
MEDIATORS OF INFLAMMATION
(2015)
Review
Immunology
Priscila de Matos Silva, Julia Bier, Lisiery Negrini Paiatto, Cassia Galdino Albuquerque, Caique Lopes Souza, Luis Gustavo Romani Fernandes, Wirla Maria da Silva Cunha Tamashiro, Patricia Ucelli Simioni
JOURNAL OF IMMUNOLOGY RESEARCH
(2015)
Review
Biotechnology & Applied Microbiology
Ana P. S. Silva, Priscila V. Coelho, Maristella Anazetti, Patricia U. Simioni
HUMAN VACCINES & IMMUNOTHERAPEUTICS
(2017)
Article
Immunology
Patricia U. Simioni, Luis G. R. Fernandes, Wirla M. S. C. Tamashiro
INTERNATIONAL JOURNAL OF IMMUNOPATHOLOGY AND PHARMACOLOGY
(2017)
Review
Chemistry, Medicinal
Debora Moitinho Abram, Luis Gustavo Romani Fernandes, Antonio Celso Saragossa Ramos Filho, Patricia Ucelli Simioni
DRUG DESIGN DEVELOPMENT AND THERAPY
(2017)
Article
Food Science & Technology
Fernanda G. D. E. Silva, Lisiery N. Paiatto, Aureo T. Yamada, Flavia M. Netto, Patricia U. Simioni, Wirla M. S. C. Tamashiro
MOLECULAR NUTRITION & FOOD RESEARCH
(2018)
Article
Multidisciplinary Sciences
Lisiery N. Paiatto, Fernanda G. D. Silva, Aureo T. Yamada, Wirla M. S. C. Tamashiro, Patricia U. Simioni
Article
Cell Biology
Rodolfo Thome, Luis Gustavo Romani Fernandes, Marcela Franco Mineiro, Patricia Ucelli Simioni, Paulo Pinto Joazeiro, Wirla Maria da Silva Cunha Tamashiro
CELLULAR IMMUNOLOGY
(2012)
Article
Multidisciplinary Sciences
Lisiery N. Paiatto, Fernanda G. D. Silva, Julia Bier, Marcia R. Brochetto-Braga, Aureo T. Yamada, Wirla M. S. C. Tamashiro, Patricia U. Simioni
Review
Food Science & Technology
Murilo Luiz Bazon, Lais Helena Silveira, Patricia Ucelli Simioni, Marcia Regina Brochetto-Braga
Article
Immunology
Marina Rodrigues de Abreu, Melissa Carolina Pereira, Patricia Ucelli Simioni, Elen Fernanda Nodari, Lisiery Negrini Paiatto, Maria Izabel Camargo-Mathias
VETERINARY IMMUNOLOGY AND IMMUNOPATHOLOGY
(2019)
Article
Entomology
Melissa Carolina Pereira, Elen Fernanda Nodari, Marina Rodrigues de Abreu, Lisiery Negrini Paiatto, Patricia Ucelli Simioni, Maria Izabel Camargo-Mathias
Summary: The brown dog tick, as the primary vector of pathogens affecting dogs globally, utilizes bioactive molecules in its saliva to modulate the immune response in host organisms. In vitro experiments show that the salivary gland extract of female dog ticks can induce a decrease in nitric oxide secretion through macrophage activation, demonstrating its potential modulatory effects on the immune system.
EXPERIMENTAL AND APPLIED ACAROLOGY
(2021)
Article
Food Science & Technology
Murilo Luiz Bazon, Luis Gustavo Romani Fernandes, Isabela Oliveira Sandrini Assugeni, Lucas Machado Pinto, Patricia Ucelli Simioni, Ricardo de Lima Zollner, Marcia Regina Brochetto Braga
Summary: The study found that rPoly p 5 does not affect NO production or the expression of co-stimulatory molecules in mouse peritoneal macrophages. However, rPoly p 5 increased IL-1 beta production in non-activated macrophages and decreased TNF-alpha and MCP-1 cytokines production in activated macrophages. The findings suggest an important role of this allergen in modulating M2 macrophage phenotypes, especially in previously activated macrophages.